Copyright
©The Author(s) 2021.
World J Cardiol. Oct 26, 2021; 13(10): 556-565
Published online Oct 26, 2021. doi: 10.4330/wjc.v13.i10.556
Published online Oct 26, 2021. doi: 10.4330/wjc.v13.i10.556
Ref. | Study type | Number of patients | Cardiac involvement | Cardiovascular comorbidities |
Wang et al[2] | Case series | 138 | 7.2% | Diabetes (10.1%); Hypertension (31.2%); CVD (14.5%); CVA |
Huang et al[4] | Prospective | 41 | 12% | Hypertension |
Guo et al[8] | Retrospective | 187 | 27.8% | Hypertension (32.6%); Diabetes (15%); CVD (11.2%); Cardiomyopathy (4.3%) |
Zhou et al[12] | Retrospective | 191 | 17% | Hypertension (30%); Diabetes (19%); CAD (8%) |
Shi et al[25] | Descriptive | 416 | 19.7% | Hypertension (30.5%); Diabetes (14.4%); CVA (5.3%); CAD (10.6%) |
Yang et al[33] | Retrospective, observational study | 52 | 23% | Diabetes (17%); CVD (10%); CVA (13.5%) |
VTE risk factor | VTE risk score |
Previous VTE | 3 |
Known thrombophilia1 | 2 |
Current lower limb paralysis or paresis | 2 |
History of cancer | 2 |
ICU/CCU stay | 1 |
Complete immobilization > 24 h | 1 |
Age > 60 yr | 1 |
- Citation: Bhandari M, Pradhan A, Vishwakarma P, Sethi R. Coronavirus and cardiovascular manifestations- getting to the heart of the matter. World J Cardiol 2021; 13(10): 556-565
- URL: https://www.wjgnet.com/1949-8462/full/v13/i10/556.htm
- DOI: https://dx.doi.org/10.4330/wjc.v13.i10.556